510 results about "Hyperlipidemia" patented technology

The invention discloses a strain of bifidobacterium animalis dipro-60 and a preparation method thereof. The invention further discloses a preparation, and the preparation contains the bifidobacterium animalis dipro-60. The bifidobacterium animalis dipro-60 used in the invention has the ability of producing bile salt hydrolase BSH, the ability of reducing cholesterol, the ability of inhibiting helicobacter pylori and the ability of reducing inflammatory factor TNF-alpha; further animal experiments show that the dipro-60 can improve lipid metabolism related diseases, can significantly reduce weight gain of obese mice induced by high fat, significantly reduce the liver weight of the obese mice, reduce the content of triglyceride and blood sugar in blood, improve intestinal barriers and improve the lipid metabolism related diseases, and the dipro-60 can improve the lipid metabolism related diseases. Liver lipid accumulation caused by obesity or hyperlipidemia is improved, and bone loss caused by obesity or hyperlipidemia is improved.

The invention provides a multi-source heterogeneous data integrated coronary heart disease accurate prediction method, which comprises the following steps: acquiring various physiological signals of a patient in real time, the physiological signals comprising ST segment change characteristics and basic cycle function parameters in electrocardiosignals, and obtaining a multi-source signal data set; according to the joint data set, analyzing instantaneous fluctuation characteristics of a vascular resistance index in a postprandial hyperlipemia window period, extracting a vascular resistance fluctuation amplitude from the instantaneous fluctuation characteristics, and if it is detected that the fluctuation amplitude exceeds a preset threshold range, marking the window as a high-risk time window; if the score value exceeds a preset threshold value, triggering a coronary heart disease early warning signal according to the comprehensive risk score value in combination with a feature mode of a coronary heart disease hidden period in historical data; and storing the current high-risk time window characteristics and the blood sugar and blood fat curve change trend through a triggered coronary heart disease early warning signal to obtain structured risk archive data.

The invention relates to the field of microorganisms, and discloses a strain of lactobacillus acidophilus and application of the lactobacillus acidophilus in preparation of drugs for preventing and / or treating hyperlipidemia and hyperglycemia, the preservation number of the lactobacillus acidophilus is CGMCC No.33155, the strain can generate lactic acid, is resistant to acid and cholate, and has strong self-aggregation ability and hydrophobic ability. The strain provided by the invention can promote the decomposition of fat and sugar by degrading cholesterol and inhibiting the activity of alpha-glucosidase and alpha-amylase, can reduce the expression levels of blood sugar, blood fat and inflammatory factors of hyperlipidemia and hyperglycemia mice, and provides a new idea for preparing medicines for preventing and / or treating hyperglycemia and hyperlipidemia.

The invention belongs to the field of biomedicine, and particularly relates to application of ABCG1 in diagnosis or auxiliary diagnosis of HIV (human immunodeficiency virus) combined hyperlipidemia. Through detection, the expression of the ABCG1 in the blood of a patient with HIV combined with hyperlipidemia is obviously reduced, the ABCG1 is verified to have the characteristics of high sensitivity and high specificity, whether hyperlipidemia exists in an HIV infected group or not can be diagnosed or diagnosed in an auxiliary manner by detecting the expression of the ABCG1, guidance is provided for early intervention of hyperlipidemia in the HIV infected group, and the method is suitable for clinical application. Wide clinical application prospects are realized.

The invention discloses a lactobacillus paracasei SX-M1559 strain and application thereof in preparation of drugs for reducing blood sugar and lipid and resisting inflammation, and belongs to the technical field of microorganisms. The invention discloses a lactobacillus paracasei SX-M1559, and the preservation number of the lactobacillus paracasei SX-M1559 is CCTCC (China Center For Type Culture Collection) NO: M 2025030. According to the lactobacillus paracasei SX-M1559 and the application thereof in preparation of the medicine for reducing blood sugar, blood fat and inflammation, the SX-M1559 is separated from fresh feces of long-life old people, teai county, Zhanjiang city, Guangdong province, the glucose content in a zebra fish hyperglycemia model body and the fat content in a zebra fish hyperlipidemia model body can be remarkably reduced, and the effect of reducing blood sugar, blood fat and inflammation is achieved. The invention provides a theoretical reference and a guidance basis for developing a probiotic preparation for preventing or treating hyperlipidemia, diabetes mellitus and inflammatory bowel disease by utilizing the new strain SX-M1559 of the casei paracasei.

A GLP-1-Fc-FGF21 double-target fusion protein composition and the use thereof. The composition comprises a GLP-1-Fc-FGF21 fusion protein and a buffer solution. In the composition, by means of adding the buffer solution, the generation of visible particles can be effectively controlled, and the stability of the GLP-1-Fc-FGF21 fusion protein is improved, so that the shelf life of a product can be prolonged. The composition can be used for treating and / or preventing metabolic diseases, such as diabetes, hyperlipidemia, obesity and diseases related to fatty liver.

A pharmaceutical composition comprising a first RNAi agent and a second RNAi agent, the first RNAi agent comprising one or more first and / or one or more first siRNA conjugates capable of inhibiting APOC3 mRNA; a second RNAi agent comprising one or more second siRNAs and / or one or more second siRNA conjugates capable of inhibiting PCSK9 mRNA; the weight ratio of the first RNAi agent to the second RNAi agent in the pharmaceutical composition is (10: 1)-(1: 10) based on the total amount of the siRNA and the siRNA group. The pharmaceutical composition and the treatment method can effectively treat and / or prevent diseases or symptoms related to hyperlipidemia.

The invention discloses application of fisetin or a salt thereof in medicine preparation, the compound is used for treating or preventing obesity cardiomyopathy, preferably heart diseases caused by hyperlipidemia, but is not limited to the inducer, and specifically, the medicine can inhibit or improve various obesity cardiomyopathy.

The invention belongs to the field of microorganisms and the technical field of medicines, and particularly relates to a bacterium capable of improving lipid metabolism diseases and application of the bacterium. The bacterium capable of improving the lipid metabolism disease is lactobacillus gasseri SPUB4211, has been preserved in the China General Microbiological Culture Collection Center on October 30, 2023, and has the preservation number of CGMCC NO.28809. The lactobacillus gasseri SPUB4211 has been preserved in the China General Microbiological Culture Collection Center; or the lactobacillus gasseri SPUB4209 is preserved in the China General Microbiological Culture Collection Center on October 30, 2023, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28808. The lactobacillus gasseri SPUB4209 has been preserved in the China General Microbiological Culture Collection Center). The lactobacillus gasseri SPUB4211 and the lactobacillus gasseri SPUB4209 provided by the invention have relatively strong lipid metabolism improving capability, and are verified by respectively detecting biochemical indexes of serum and biochemical indexes in liver of mice in a high fat diet induced hyperlipidemia model and a non-alcoholic fatty liver disease model and by liver tissue slices, and the lactobacillus gasseri SPUB4211 and the lactobacillus gasseri SPUB4209 have good artificial gastric juice, good anti-inflammatory and anti-inflammatory effects and good anti-inflammatory and anti-inflammatory effects. And artificial intestinal juice tolerance.

The invention belongs to the technical field of gene editing, and discloses a base editor system and application. According to the invention, a heterologous peptide sequence is inserted into IscB protein, the obtained peptide embedded IscB is fused with deaminase or glycosylase to construct a base editor, and DNA base editing is carried out. According to the base editor system, the size limitation is overcome, and single AAV delivery is achieved; the editing efficiency is obviously improved; the broad-spectrum applicability is realized; the system optimization is more flexible; the method has efficient editing potential in vivo, and the off-target effect is reduced. The invention provides an important new strategy for hyperlipemia treatment and provides a basis for gene therapy of other hereditary diseases.

The invention belongs to the technical field of protein peptide preparation, and particularly relates to mushroom peptide prepared based on Maillard reaction and application of the mushroom peptide to preparation of products with the effects of reducing blood pressure, blood sugar, blood fat and uric acid and antioxidant activity. The mushroom peptide disclosed by the invention has the effects of remarkably reducing blood pressure, blood sugar, blood fat and uric acid and resisting oxidation, and can be used as an auxiliary therapeutic agent or functional food for four high diseases such as hypertension, hyperlipidemia, diabetes mellitus and hyperuricemia and oxidative stress related diseases.

The invention belongs to the field of medicine application, and particularly discloses application of sarcosine serving as a unique active component to preparation of medicine for preventing and treating obesity and / or hyperlipidemia. The test of treating old mice with sarcosine proves that the sarcosine can reduce the total body mass and fat mass and reduce the body fat rate under the condition that the absolute lean body mass is not influenced. Through tissue staining and biochemical analysis, it is determined that sarcosine can reduce the cross sectional area of visceral adipose tissue (VAT) cells, up-regulate expression of a marker UCP1 of brown adipose tissue in visceral adipose tissue and remarkably reduce the level of triglyceride in plasma. The sarcosine has practical application value in treatment of obesity and hyperlipidemia.

The invention relates to a GLP-1-Fc-FGF21 double-target fusion protein composition and an application thereof. The composition is prepared from the GLP-1-Fc-FGF21 fusion protein and a buffer solution. According to the composition disclosed by the invention, by adding the buffer solution, the generation of visible foreign matters can be effectively controlled, and the stability of the GLP-1-Fc-FGF21 fusion protein can be improved, so that the shelf life of the product can be prolonged, and the composition disclosed by the invention can be used for treating and / or preventing metabolic diseases, such as diabetes mellitus, hyperlipidemia, obesity and fatty liver related diseases.

Disclosed is a strain of Bifidobacterium longum subsp. longum named dipro-O. The Bifidobacterium longum subsp. longum dipro-O used in the present invention has the ability to overproduce BSH, the ability to reduce cholesterol, and the ability to metabolize tryptophan into indole-3-lactic acid, can effectively reduce body weight, significantly lower insulin resistance levels resulting from high-fat diets, reduce the expression of the inflammatory cytokine TNF-α, significantly lower the levels of total cholesterol (TC) and low-density lipoprotein (LDL) in the blood, and increase the level of high-density lipoprotein (HDL), and can ameliorate disorders of the gut microbiome structure. In addition, the strain can also have an ameliorating effect on other lipid metabolism-related diseases such as hyperlipidemia, thereby providing health interventions for the host's body weight, liver, intestinal health, and blood lipid levels. Moreover, pasteurized dipro-O can also have the effect of regulating lipid metabolism, further extending the range of applications of the strain.

The invention discloses a lactobacillus mucus fermentation strain and application thereof, the lactobacillus mucus fermentation strain is preserved in Guangdong Microbial Culture Collection Center (GDMCC) on February 21, 2025, and the preservation number is GDMCCNO: 65936. The feruloyl esterase is separated and screened from white sour soup in Kailing in southeast of Guizhou province, has feruloyl esterase activity, and shows good blood fat reducing and fatty liver treating capabilities in a HepG2 high-fat cell model and a high-fat zebra fish model. The compound has a good prospect in the development of products for preventing or treating hyperlipidemia and fatty liver and relieving obesity.

The invention relates to a lactobacillus rhamnosus YYSJ019 strain for relieving obesity and application of the lactobacillus rhamnosus YYSJ019 strain. The lactobacillus rhamnosus YYSJ019 strain is classified and named as lactobacillus rhamnosus, and the preservation number of the lactobacillus rhamnosus YYSJ019 strain is CGMCC (China General Microbiological Culture Collection Center) No.33472. The strain has good tolerance and high surface hydrophobicity in gastric juice, and has the potential of smoothly entering the gastrointestinal tract of a human body; the bacterial strain has excellent intestinal adhesion capability, and provides a basis for continuously playing a probiotic effect; the strain can slow down weight gain of obese mice and improve fat accumulation, liver injury and inflammation in bodies of the obese mice; the blood sugar metabolism capability and the blood fat metabolism capability can also be improved, and the potential of preventing and treating hyperglycemia or hyperlipidemia is achieved; in addition, a mouse small intestine endocrine cell line (STC-1 cell line) can be stimulated to generate the glucagon-like peptide-1, and the glucagon-like peptide-1 has the potential of improving diseases caused by insufficient secretion of the glucagon-like peptide-1; the effects of reducing uric acid in vitro and reducing uric acid in vivo are achieved, and the potential of preventing and treating hyperuricemia is achieved.

The invention belongs to the technical field of health-care food, and particularly relates to a sacha inchi oil-based gel candy with functions of reducing hypertension, hyperglycemia and hyperlipidemia and a preparation method thereof, and the sacha inchi oil-based gel candy comprises the following components: 1) a main component: 30-70% of sacha inchi oil; 2) a blood fat reducing synergistic component which is one or a combination of more of 0.5%-5% of phytosterol, 0.1%-2% of a red yeast rice extract and 0.01%-0.5% of sugarcane octacosanol; 3) a hypoglycemic synergistic component, which comprises one or a combination of more of 5%-20% of inulin / fructo-oligosaccharide, 0.5%-5% of a bitter gourd extract, 0.5%-5% of a mulberry leaf extract and 10-200 [mu] g / grain of chromium; 4) an antihypertensive synergistic component, wherein the antihypertensive synergistic component is one or a combination of more of 500-5000FU / grain of nattokinase, 0.5-5% of a celery seed extract and 1-8% of a hawthorn extract; through scientific compounding, the sacha inchi oil and various synergistic components exert a combined effect, and meanwhile, auxiliary regulation is carried out on blood sugar, blood fat and blood pressure; the main components are derived from natural plant extracts or functional grease, so that the health-care product is high in safety and suitable for daily health care.

The invention discloses a preparation method of soybean protein-phycocyanin double-protein oil gel type plant-based cheese, and belongs to the technical field of food processing. The method comprises the following steps: (1) preparing soybean protein-phycocyanin double proteins; (2) ultrasonic preparation of a double-protein solution; (3) compounding plant-based cheese raw materials; (4) stirring and homogenizing the compound liquid; and (5) heating, cooling and forming. The gel type plant-based cheese adopts a compounding mode of two plant proteins, integrates the nutritional advantages of the two proteins, can play a role of a cheese substitute, is green, safe, natural and healthy, reduces the occurrence risk of hypertension, hyperlipidemia, diabetes and other diseases caused by animal fat and the like, and promotes the development and application of plant-based food.

The invention provides application of qi and blood strengthening oral liquid in preparation of a medicine for improving hyperlipidemia, and belongs to the technical field of medicine preparations. According to the invention, the mass ratio relationship among the components and the preparation method thereof are researched, and especially in the preparation process, the traditional Chinese medicine components are extracted by means of high-pressure steam heating, vacuum concentration and the like under different pressures in batches and stages, so that the obtained oral liquid for consolidating qi and blood is high in content of effective components, and has a good effect on consolidating qi and blood. The oral liquid for consolidating qi and blood can significantly improve hyperlipidemia, and has potential clinical application value.

The present disclosure provides GLP-1 / GIP and GLP-1 / GCG dual receptor agonists comprising incretin analog polypeptides and use thereof in the treatment or prevention of Type 2 diabetes mellitus (T2DM), hyperlipidemia / dyslipidemia, metabolic syndromes, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction- associated steatohepatitis (MASH), neurodegenerative disorders, fibrosis, cardiovascular risks, and / or obesity.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating glycolipid metabolic diseases and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15-19 parts of coptis chinensis, 10-15 parts of rhodiola rosea, 10-20 parts of gynostemma pentaphylla, 9-12 parts of kapok, 10-15 parts of soapberry, 9-15 parts of salvia miltiorrhiza, 10-15 parts of rhizoma alismatis, 9-12 parts of oriental wormwood, 9-12 parts of radix bupleuri, 5-10 parts of semen cassiae, 10-15 parts of rhizoma anemarrhenae, 10-15 parts of hawthorn, 6-9 parts of polygonum cuspidatum and 5-10 parts of fructus aurantii. The traditional Chinese medicine composition disclosed by the invention has the effects of inhibiting hyperlipidemia, hyperglycemia and hepatic lipid accumulation and relieving insulin resistance, and has a remarkable curative effect on relieving and treating glycolipid metabolic diseases.

The present invention provides a pharmaceutical composition of a single dosage form for treating hypertension and hyperlipidemia. According to the present invention, compartments comprising a drug are formulated in separate forms so as to solve problems related to the dissolution and absorption of the drug due to drug interaction, and a biologically equivalent preparation can be obtained when compared to conventional single preparation.

The invention relates to a bezafibrate-atenolol crystal compound as well as preparation and application thereof. Specifically, the invention discloses a bezafibrate-atenolol crystal compound, and the bezafibrate-atenolol crystal compound has the advantages that the solubility of bezafibrate is obviously improved, the pharmacokinetic performance is obviously improved, and the lipid-lowering effect is obviously improved. The invention also discloses preparation of the crystal compound and application of the crystal compound in prevention and / or treatment of hyperlipidemia.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as small interfering RNA (siRNA) molecules, able to inhibit proprotein convertase subtilisin kexin 9 (PCSK9) gene expression. Also disclosed are pharmaceutical compositions that include PCSK9 RNAi agents and methods of use thereof. The PCSK9 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the PCSK9 RNAi agents in vivo provides for in vivo provides for inhibition of PCSK9 gene expression and thereby reduction of PCSK9 protein. The RNAi agents can be used in methods of treatment of diseases or disorders mediated at least in part by PCSK9 gene expression, including among others hypercholesterolemia, familial hypercholesterolemia including heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH), familial hypobetalipoproteinemia, hyperlipidemia, coronary artery disease, polygenic dyslipidemia, heart disease, cardiovascular disease (CVD) including clinical atherosclerotic cardiovascular disease (ASCVD).

The invention belongs to the field of functional food, health care products and medicines, and particularly relates to okra polysaccharide with a function of improving metabolic syndrome as well as a preparation method and application of the okra polysaccharide. The preparation method of the okra polysaccharide comprises the steps of pretreatment, alcohol soaking of raw materials, extraction of filtrate, alcohol precipitation, dialysis, concentration and freeze drying. The okra polysaccharide provided by the invention can improve metabolic syndrome indexes including obesity, hyperlipidemia, hyperglycemia, hypertension, liver inflammation, flora disorder and the like, the comprehensive improvement effect is better than that of commercial apple pectin, citrus pectin and inulin, and the okra polysaccharide can be used as prebiotics to enrich intestinal beneficial bacteria deficiency caused by metabolic syndrome. The sources of natural medicines and health-care products for preventing and treating the metabolic syndrome are widened.

The present invention provides a Chinese medicine composition for treating hyperlipidemia, and a preparation method and application thereof. The Chinese medicine composition, by weight, comprises: 4-12 parts of hawthorn, 8-12 parts of salvia miltiorrhiza, 4-12 parts of panax notoginseng and 4-12 parts of pearly buds. The preparation method comprises: (1) crushing the Chinese medicinal materials hawthorn, salvia miltiorrhiza, panax notoginseng and pearly buds to obtain a powder; (2) using an ethanol aqueous solution as an extraction solvent to extract the powder, and concentrating the obtained extract to obtain a compound extract of the Chinese medicine composition. Although pearly buds have no effect on lowering blood lipids, when it is used in combination with hawthorn, salvia miltiorrhiza and panax notoginseng, it can improve the blood lipid lowering effect of the hawthorn, salvia miltiorrhiza and panax notoginseng composition.

The invention discloses a traditional Chinese medicine constitution identification method and device, a storage medium and a server. The method comprises the following steps: acquiring a human face spectrum sample and blood fat contents of a tested crowd; inputting the human face spectrum sample into a pre-constructed hyperlipidemia risk prediction model to obtain a target human face spectrum sample with hyperlipidemia in the tested crowd and a first target blood fat four-item content corresponding to the target human face spectrum sample; making corresponding labels on the basis of the target face spectrum samples, corresponding first target blood fat four-item contents and traditional Chinese medicine constitution categories, and training the model through training samples obtained by making the corresponding labels to obtain a traditional Chinese medicine constitution identification model; obtaining a to-be-detected human face spectrum sample, and inputting the sample into the traditional Chinese medicine constitution identification model to obtain the content of four second target blood lipids suffering from hyperlipidemia in the detected crowd and a traditional Chinese medicine constitution identification result corresponding to the content of the four second target blood lipids; the technical problem that enough support cannot be accurately provided for treatment and prevention of patients with the lipemia is solved.

The present invention relates to the field of Chinese medicinal materials, and in particular to a Chinese medicine composition, a medicine, and a preparation method and application thereof for treating hyperuricemia with hyperlipidemia. The Chinese medicine composition and medicine provided by the present invention can intervene in the treatment of asymptomatic hyperuricemia combined with hyperlipidemia, and compared with traditional uric acid-lowering drugs (febuxostat), serum uric acid can be quickly reduced, and the uric acid level can be basically controlled within a normal range. No gout symptoms are found in patients within 6 months of treatment, and complications such as hypertension, hyperglycemia, and cardiovascular and cerebrovascular diseases can be significantly reduced, and the quality of life of patients can be improved; it can also overcome the technical deficiencies of uric acid-lowering drugs, such as many adverse reactions, difficult to sustain therapeutic effects, and limited applicable populations, and has the advantages of small side effects, long-lasting efficacy, and multiple drug targets.

The invention discloses a myocardial ischemia reperfusion injury animal model construction method and application thereof in the technical field of model animal preparation. The method comprises the steps of hypertension and hyperlipidemia pretreatment, standardized ischemia-reperfusion operation, immune microenvironment regulation and control and model evaluation and verification. According to the invention, model construction is carried out on an integrated model operation table, so that a standardized ischemia-reperfusion process is realized, reproducibility of a myocardial injury degree and an immune cell infiltration rule of the model is realized, and suitability of the model and nano-drug research is enhanced; and a reliable tool is provided for research and development of targeted drugs such as immune cell membrane coated nanoparticles.

The invention discloses an intelligent wearable product for realizing three-dimensional health monitoring management early warning and multi-dimensional first aid. An index monitoring module monitors human health related indexes in real time all day long; the risk early warning module judges the high, medium and low risk levels of each heart and cerebral vessel index and makes corresponding early warning reminding; the health conditioning module helps to regulate and improve hyperglycemia, hypertension and hyperlipidemia, and provides personalized scientific healthy diet, scientific exercise improvement suggestions and health conditioning schemes for improving emotion and sleep; the health management module generates a motion target recommendation, a sleep target recommendation, a health report and a health portrait; when it is judged that the user is in a high-risk early warning state, the emergency help seeking module automatically enters a first-aid mode, automatically dials to seek help outwards, automatically answers an incoming call, quickly positions an incident point, a nearby medical unit and an AED, and displays a pre-stored medical health electronic file, so that multi-dimensional deployment and control and defense are achieved, and the life and health of the user are protected in a three-dimensional mode.